Nan-Ak Wiboonkhwan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nan-Ak Wiboonkhwan has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Thakerng Pitakteerabundit
Department of Surgery Faculty of Medicine, Prince of Songkla University Songkhla Thailand
5 shared publications - Tortrakoon Thongkan
Department of Surgery Faculty of Medicine, Prince of Songkla University Songkhla Thailand
5 shared publications - Kuo-Hsin Chen
Division of General Surgery, Department of Surgery, Far-Eastern Memorial Hospital, New Taipei City, Taiwan
2 shared publications - Mu-Ching Tsai2 shared publications
Chun-Chieh Huang
1 shared publicationJiann-Ming Wu
1 shared publication
Latest Publications
- 28 May 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (8) , 7546-7547
ASO Author Reflections: Precision in Reoperative Pancreas-Preserving Surgery for Pancreatic Adenocarcinoma
- 28 May 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (8) , 7546-7547
ASO Author Reflections: Precision in Reoperative Pancreas-Preserving Surgery for Pancreatic Adenocarcinoma
- Open Access
- 15 May 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (8) , 7533
Fluorescence-Guided Remnant-Sparing Laparoscopic Distal Pancreatectomy for Metachronous Pancreatic Cancer Following Whipple Procedure
Completion total pancreatectomy is the traditional approach for metachronous pancreatic cancer developing after pancreaticoduodenectomy (PD). However, this
- 15 May 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (8) , 7533
Open AccessFluorescence-Guided Remnant-Sparing Laparoscopic Distal Pancreatectomy for Metachronous Pancreatic Cancer Following Whipple Procedure
Completion total pancreatectomy is the traditional approach for metachronous pancreatic cancer developing after pancreaticoduodenectomy (PD). However, this
- 9 March 2026
- Published by Wiley in Anz Journal of Surgery
Oncological Outcomes After Margin‐Negative ( R0 ) Resection in Borderline Resectable Pancreatic Adenocarcinoma: Upfront Surgery Versus Neoadjuvant Treatment—A Contemporary Review
Background: Achieving a margin‐negative (R0) resection in borderline resectable pancreatic cancer (BRPC) is a critical prognostic determinant. The optimal clinical strategy—neoadjuvant therapy (NAT) versus upfront surgery (UFS)—remains a key clinical question. Methods: This narrative review synthesized contemporary evidence from studies published between 2009 and 2025, encompassing a total of 5598 patients with BRPC. The analysis compared oncological outcomes between NAT and UFS, specifically focusing on resection rates, R0 resection frequency, and median overall survival (OS). Mixed‐cohort studies lacking BRPC subgroup analysis were excluded. Results: Evidence from both comparative and single‐arm studies indicated that the majority of cohorts achieved significantly higher R0 resection rates and improved median OS following NAT. Resection rates after NAT ranged from 29% to 90%, whereas UFS cohorts reported rates between 62% and 92%. Although resection was more frequent in UFS groups, NAT cohorts demonstrated superior oncological margins; R0 rates in NAT groups ranged from 23% to 100% compared to 14% to 90% in UFS groups. This translated into a survival benefit, with NAT groups achieving a median OS of 11.0 to 43.9 months versus 11.6 to 27.8 months for UFS. NAT also facilitated superior pathological downstaging and reduced lymph node positivity. Conclusion: Neoadjuvant therapy, utilizing potent multi‐agent regimens, significantly improves R0 resection rates and overall survival in BRPC and is increasingly recognized as the preferred clinical strategy. Currently, this survival benefit is not clearly established for patients with upfront resectable disease.
- 9 March 2026
- Published by Wiley in Anz Journal of Surgery
Oncological Outcomes After Margin‐Negative ( R0 ) Resection in Borderline Resectable Pancreatic Adenocarcinoma: Upfront Surgery Versus Neoadjuvant Treatment—A Contemporary Review
Background: Achieving a margin‐negative (R0) resection in borderline resectable pancreatic cancer (BRPC) is a critical prognostic determinant. The optimal clinical strategy—neoadjuvant therapy (NAT) versus upfront surgery (UFS)—remains a key clinical question. Methods: This narrative review synthesized contemporary evidence from studies published between 2009 and 2025, encompassing a total of 5598 patients with BRPC. The analysis compared oncological outcomes between NAT and UFS, specifically focusing on resection rates, R0 resection frequency, and median overall survival (OS). Mixed‐cohort studies lacking BRPC subgroup analysis were excluded. Results: Evidence from both comparative and single‐arm studies indicated that the majority of cohorts achieved significantly higher R0 resection rates and improved median OS following NAT. Resection rates after NAT ranged from 29% to 90%, whereas UFS cohorts reported rates between 62% and 92%. Although resection was more frequent in UFS groups, NAT cohorts demonstrated superior oncological margins; R0 rates in NAT groups ranged from 23% to 100% compared to 14% to 90% in UFS groups. This translated into a survival benefit, with NAT groups achieving a median OS of 11.0 to 43.9 months versus 11.6 to 27.8 months for UFS. NAT also facilitated superior pathological downstaging and reduced lymph node positivity. Conclusion: Neoadjuvant therapy, utilizing potent multi‐agent regimens, significantly improves R0 resection rates and overall survival in BRPC and is increasingly recognized as the preferred clinical strategy. Currently, this survival benefit is not clearly established for patients with upfront resectable disease.
- Open Access
- 24 February 2026
- Published by Elsevier in Asian Journal of Surgery
- Vol. 49 (10) , 5281-5282
Laparoscopic radical multivisceral resection of T4 gallbladder cancer: Technical report with a video vignette
- 24 February 2026
- Published by Elsevier in Asian Journal of Surgery
- Vol. 49 (10) , 5281-5282
Open AccessLaparoscopic radical multivisceral resection of T4 gallbladder cancer: Technical report with a video vignette
- Open Access
- 6 January 2026
- Published by Elsevier in Asian Journal of Surgery
- Vol. 49 (7) , 4162-4163
Laparoscopic pancreaticoduodenectomy with SMV resection and artificial vascular reconstruction for pancreatic ductal adenocarcinoma: With a video vignette
- 6 January 2026
- Published by Elsevier in Asian Journal of Surgery
- Vol. 49 (7) , 4162-4163
Open AccessLaparoscopic pancreaticoduodenectomy with SMV resection and artificial vascular reconstruction for pancreatic ductal adenocarcinoma: With a video vignette
- 9 May 2025
- Published by Wiley in Anz Journal of Surgery
Safety of Single Preoperative Dose of Enoxaparin for Hepatectomy: A Study in a Country With Low Venous Thromboembolism Incidence
Background: Postoperative venous thromboembolism (VTE) prophylaxis for hepatectomy is debated in low‐VTE incidence regions like Thailand due to bleeding risks. This study evaluated single‐dose preoperative enoxaparin safety for VTE prophylaxis, focusing on post‐hepatectomy hemorrhage (PHH).Methods: This retrospective review compared VTE and PHH incidence before (no prophylaxis) and after implementation of a single preoperative dose of enoxaparin 40 mg for all patients undergoing elective hepatectomy in a center in Thailand. PHH and post‐hepatectomy liver failure (PHLF) were defined per International Study Group of Liver Surgery criteria. Factors associated with PHH were analyzed using logistic regression.Results: One hundred eighty‐six patients underwent elective hepatectomy (mean age 58 years). Fifty‐two percent underwent major hepatectomy. PHLF occurred in 11% of patients. VTE occurred in 0% (0/96) of the pre‐protocol and 1.1% (1/90) of the post‐protocol group. PHH rate was 3.8%, with no difference between pre‐protocol (3/96) and post‐protocol groups (4/90). Factors associated with PHH were intraoperative transfusion > 2 units (OR 33.3; 95% CI 1.9–587.7) and PHLF (OR 17.2; 95% CI 2.1–140.8), but not enoxaparin (OR 1.9; 95% CI 0.3–12.8).Conclusions: Single preoperative enoxaparin did not increase PHH risk in this low VTE incidence cohort and may be considered for VTE prophylaxis in similar populations.
- 9 May 2025
- Published by Wiley in Anz Journal of Surgery
Safety of Single Preoperative Dose of Enoxaparin for Hepatectomy: A Study in a Country With Low Venous Thromboembolism Incidence
Background: Postoperative venous thromboembolism (VTE) prophylaxis for hepatectomy is debated in low‐VTE incidence regions like Thailand due to bleeding risks. This study evaluated single‐dose preoperative enoxaparin safety for VTE prophylaxis, focusing on post‐hepatectomy hemorrhage (PHH).Methods: This retrospective review compared VTE and PHH incidence before (no prophylaxis) and after implementation of a single preoperative dose of enoxaparin 40 mg for all patients undergoing elective hepatectomy in a center in Thailand. PHH and post‐hepatectomy liver failure (PHLF) were defined per International Study Group of Liver Surgery criteria. Factors associated with PHH were analyzed using logistic regression.Results: One hundred eighty‐six patients underwent elective hepatectomy (mean age 58 years). Fifty‐two percent underwent major hepatectomy. PHLF occurred in 11% of patients. VTE occurred in 0% (0/96) of the pre‐protocol and 1.1% (1/90) of the post‐protocol group. PHH rate was 3.8%, with no difference between pre‐protocol (3/96) and post‐protocol groups (4/90). Factors associated with PHH were intraoperative transfusion > 2 units (OR 33.3; 95% CI 1.9–587.7) and PHLF (OR 17.2; 95% CI 2.1–140.8), but not enoxaparin (OR 1.9; 95% CI 0.3–12.8).Conclusions: Single preoperative enoxaparin did not increase PHH risk in this low VTE incidence cohort and may be considered for VTE prophylaxis in similar populations.
- 5 July 2022
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 84 (S2) , 500-503
Novel Trocar-Free Gastric Retractor in Laparoscopic Distal Pancreatectomy
- 5 July 2022
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 84 (S2) , 500-503
Novel Trocar-Free Gastric Retractor in Laparoscopic Distal Pancreatectomy
- 15 December 2021
- Published by Wiley in Anz Journal of Surgery
- Vol. 92 (7-8) , 1955-1957
Photographic analysis of the anatomical landmarks in bile duct injury
- 15 December 2021
- Published by Wiley in Anz Journal of Surgery
- Vol. 92 (7-8) , 1955-1957
Photographic analysis of the anatomical landmarks in bile duct injury
- 4 October 2021
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 84 (4) , 888-889
Cholecystocolonic Fistula: Incidentally Diagnosed with Barium Enema
- 4 October 2021
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 84 (4) , 888-889
Cholecystocolonic Fistula: Incidentally Diagnosed with Barium Enema